-
Laekna Submits Revised Protocol for LAE102 Obesity Trial with Eli Lilly
•
Sino-US biotech Laekna Therapeutics (HKG: 2105) announced the submission of a revised clinical protocol to the US Food and Drug Administration (FDA) for LAE102, an Activin Receptor Type 2 A (ActRIIA)-targeted monoclonal antibody (mAb) co-developed with Eli Lilly & Co. (NYSE: LLY). Collaboration DetailsUnder the agreement signed between Laekna and…
-
EClinCloud Secures New Funding to Accelerate AI Innovation in Clinical Research
•
EClinCloud (Ningbo) Technology Co., Ltd., a leading AI technology company specializing in clinical research solutions, has announced the completion of a new round of financing worth tens of millions of yuan. The investment was exclusively led by Hongfeng, a renowned biopharmaceutical investment firm. This funding will further accelerate EClinCloud’s deep…
-
Eisai Transfers Pariet Rights in China to CBC Group-Controlled Peak Pharma
•
Japan-based Eisai (TYO: 4523) announced a strategic decision to transfer the rights of its proton pump inhibitor (PPI) Pariet (rabeprazole) in China to Peak Pharmaceutical, a company controlled by CBC Group. Pariet’s Market PresencePariet, with rabeprazole as its active ingredient, has been a leading prescription drug for gastrointestinal disorders such…
-
Sinovac Biotech’s SNA02-48 Gains Clinical Approval for Tetanus Prevention
•
Beijing Sinovac Biotech Co., Ltd’s (NASDAQ: SVA) subsidiary Sinovac Life Sciences Co., Ltd. and its partner Synermore Biologics announced that their Category I new drug, SNA02-48 injection, has received clinical approval from the National Medical Products Administration (NMPA). This recombinant fully human monoclonal antibody targets tetanus toxin and offers a…
-
Abbott Laboratories’ Volt PFA System Receives EU CE Mark for Atrial Fibrillation Treatment
•
US-based Abbott Laboratories (NYSE: ABT) has announced the receipt of the CE mark in the European Union (EU) for its Volt PFA System, a novel therapy for patients with atrial fibrillation (AFib). This approval marks a significant advancement in treatment options for AFib, particularly for those with complex conditions. Technology…
-
Alcon Laboratories Acquires Majority Stake in Aurion Biotech to Advance Eye Disease Cell Therapy
•
US-based eye care firm Alcon Laboratories, Inc. has announced the acquisition of a majority stake in Aurion Biotech, Inc., a clinical-stage cell therapy specialist focused on eye diseases. This strategic move aims to enhance Alcon’s portfolio in innovative ophthalmic treatments. Aurion Bio’s Leading TherapyAurion Bio’s flagship product, AURN001, is an…
-
Genmab’s Tivdak Approved in Japan for Advanced Cervical Cancer Treatment
•
Denmark-based Genmab A/S (NASDAQ: GMAB) has secured approval from the Japan Ministry of Health, Labour and Welfare for its Tivdak (tisotumab vedotin) to treat advanced or recurrent cervical cancer that has progressed on or after chemotherapy. Drug Profile and TechnologyTivdak is an antibody-drug conjugate (ADC) comprising Genmab’s human monoclonal antibody…
-
CStone Pharmaceuticals Reports 2024 Results with License Fee Growth Offsetting Drug Sales Decline
•
China-based CStone Pharmaceuticals (HKG: 2616) reported its 2024 financial results and recent business highlights. Revenues reached RMB 407.2 million (USD 56.1 million), a 12.2% year-on-year (YOY) decrease. This consisted of RMB 175 million (USD 24.1 million) in pharmaceutical product sales and RMB 232 million (USD 32 million) in license fee…
-
TransThera and Akeso Biopharma Collaborate on HCC Study with Tinengotinib and Bispecific Antibodies
•
Chinese companies TransThera Sciences (Nanjing) Inc. and Akeso Biopharma (HKG: 9926) have formed a strategic research collaboration to advance an open, multi-center Phase II study combining TransThera’s tinengotinib (TT-00420) with Akeso’s cadonilimab or ivonescimab for advanced hepatocellular carcinoma (HCC). The National Medical Products Administration (NMPA) has granted clearance for the…
-
NMPA Approves Qingfeng’s Suraxavir Marboxil for Influenza A and B Treatment
•
China’s National Medical Products Administration (NMPA) has approved suraxavir marboxil, a Category 1 drug developed by Qingfeng Pharmaceutical Group Co. Ltd’s subsidiary Jiangxi Kerui Pharmaceutical Co., Ltd, for the treatment of influenza A and B. The drug is intended for adolescents aged 12 and above as well as adults with…
-
Medtronic Launches Digital Innovation Base in Beijing’s BioPark
•
US-Irish firm Medtronic (NYSE: MDT) has inaugurated its digital medical innovation base at the BioPark in Beijing, marking the company’s first such facility in China. This strategic move underscores Medtronic’s commitment to leveraging advanced technologies in the Chinese healthcare sector. Facility Details and FocusThe new base will concentrate on developing…
-
Huadong Medicine Gains NMPA Approval for HDM3019 Rheumatoid Arthritis Trial
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced receiving approval from the National Medical Products Administration (NMPA) to initiate a clinical study for its HDM3019 in rheumatoid arthritis (RA). This marks a significant step forward for the company in expanding its portfolio in autoimmune diseases. Drug Profile and Preclinical ResultsHDM3019…
-
Lee’s Pharmaceutical Holdings Ltd Reports 32.9% Revenue Growth in 2023
•
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) released its 2023 financial report, recording HKD 1.4 billion (USD 193 million) in revenues, up 32.9% year-on-year (YOY). Licensed products continued to yield significant sales growth with HKD 553 million (USD 76 million), accounting for 39.5% of the total revenue. Patented and generic…
-
RemeGen’s 2024 Revenue Soars 58.54% on Strong Product Sales and R&D Growth
•
China-based biotech RemeGen Co., Ltd (HKG: 9995, SHA: 688331) released its 2024 financial report, recording RMB 1.717 billion (USD 236.3 million) in revenues, a 58.54% year-on-year (YOY) increase. Product sales reached RMB 1.699 billion (USD 233.9 million), up 61.9% YOY. The annual loss decreased by 2.8% YOY to RMB 1.468…
-
JW Therapeutics Sees 9% Revenue Decline in 2024 Amid Commercial Strategy Shift
•
China-based JW Therapeutics (HKG: 2126) released its 2024 financial report, recording RMB 158.2 million (USD 21.8 million) in revenue, a 9% year-on-year (YOY) decline. This decrease was primarily due to the implementation of a commercial activity optimization strategy in the second half of 2024 and a business personnel organizational efficiency…
-
Ascentage Pharma’s Revenue Soars 342% in 2024 on Strong Drug Sales and Partnerships
•
China-based Ascentage Pharma Group International (NASDAQ: AAPG, HKG: 6855) unveiled its 2024 financials, showing revenues skyrocketing 342% year-on-year (YOY) to RMB980 million (USD135 million). This remarkable growth was primarily driven by an option payment from Japanese partner Takeda and robust sales of olverembatinib, the novel BCR-ABL1 tyrosine kinase inhibitor (TKI),…
-
Shanghai Pharmaceuticals Reports 5.75% Revenue Growth in 2024 with Innovation Initiatives
•
China’s Shanghai Pharmaceuticals (SPH; SHA: 601607, HKG: 2607) released its 2024 financial results, showing total revenues up 5.75% year-on-year (YOY) to RMB 275.251 billion (USD 37.9 billion). Pharmaceutical industry and business sales reached RMB 22.731 billion (USD 3.3 billion) and RMB 251.5 billion (USD 34.6 billion) respectively, with the latter…
-
YiChang HEC’s Yiqibuvir Approved by NMPA for Chronic HCV Infection
•
China-based YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG: 1558) announced receiving marketing approval from the National Medical Products Administration (NMPA) for its Category 1 drug yiqibuvir. The non-structural protein 5B (NS5B) inhibitor is approved for use in combination with netanasvir in adult chronic hepatitis C virus (HCV) infections of genotypes…
-
Luye Pharma’s Shandong Boan Bio Reports 17.5% Revenue Growth in 2024
•
China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary Shandong Boan Biotechnology Co., Ltd (HKG: 6955) released its 2024 financial report, showing revenues growing 17.5% year-on-year (YOY) to RMB726.3 million (USD100 million). This growth was primarily driven by BA1101, a biosimilar of Roche’s Avastin (bevacizumab), and BA6101, a version of Amgen’s…
-
MicroPort CardioFlow Medtech Reports 7.5% Revenue Growth in 2024 Driven by Global Expansion
•
China-based MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160) announced its 2024 financial report, recording RMB362 million (USD50 million) in revenue, a 7.5% year-on-year (YOY) increase. This growth was driven by the ongoing global commercialization of its flagship products, VitaFlow Liberty and Alwide Plus. The period also saw the official launch…
